EUVIMEDOpdag EUVIMED
Open access · CC BY 4.0

Physicochemical and biological profiles of a by-product of human donor plasma fractioning

Larisa T. Volova, Nikolai A. Ryabov, Olga A. Karyakina, Violetta V. Boltovskaya, Oksana A. Gusyakova, Irina F. Nefedova, Denis G. Alekseev, Sergei A. Goncharenko

Science and Innovations in Medicine · 2026-10-14 · 11 (4) · 261-268

DOI: 10.35693/sim706425 ↗

At a glance

Journal article in Science and Innovations in Medicine, published online on 2026-10-14. Written by Larisa T. Volova and 7 co-authors. 15 references. The full text is freely available (open access, CC BY 4.0).

AbstractBibliografiske oplysningerCiteRelated studies

Abstract (original language)

Aim: to perform an integrated physicochemical and biological analysis of fibrinogen-containing precipitate No. 1 (FР No. 1), a by-product of donor plasma fractionation, and to evaluate its potential as a raw material for biomedical applications. Material and methods. A multi-method approach was employed, including Fourier-transform infrared (FTIR) spectroscopy, UV spectrophotometry, scanning electron microscopy (SEM), SDSPAGE electrophoresis, quantitative determination of protein mass fraction, assessment of fibrinogen extraction yield in citrate buffer and phosphate-buffered saline (37 °C, 5 hours), as well as in vitro biological testing on human dermal fibroblast cultures.

Results

FP No. 1 was found to preserve the structural integrity of fibrinogen with low levels of impurities. The lyophilizate formed porous fibrin matrices with pore sizes ranging from 100 to 180 μm. Cell viability upon contact with the material reached 96.5 % (p 0.05), confirming the absence of cytotoxicity. The protein mass fraction in the dry substance was 77 %. Under optimal extraction conditions, the fibrinogen yield reached 21.9 % (citrate buffer) and 21.5 % (phosphate-buffered saline).

Conclusion

FP No. 1 represents a highly promising secondary protein raw material for the development of bioinks for 3D bioprinting, wound dressings, and tissue-engineered constructs. These findings strongly advocate for the rational reintegration of plasma fractionation byproducts into hightechnology biomedical applications.

Cite

APA

Volova, L. T., Ryabov, N. A., Karyakina, O. A., Boltovskaya, V. V., Gusyakova, O. A., Nefedova, I. F., Alekseev, D. G., & Goncharenko, S. A. (2026). Physicochemical and biological profiles of a by-product of human donor plasma fractioning. Science and Innovations in Medicine, 11(4), 261-268. https://doi.org/10.35693/sim706425

Vancouver

Volova LT, Ryabov NA, Karyakina OA, Boltovskaya VV, Gusyakova OA, Nefedova IF, et al. Physicochemical and biological profiles of a by-product of human donor plasma fractioning. Science and Innovations in Medicine. 2026;11(4):261-268. doi:10.35693/sim706425

BibTeX
@article{Volova2026,
  author = {Volova, Larisa T. and Ryabov, Nikolai A. and Karyakina, Olga A. and Boltovskaya, Violetta V. and Gusyakova, Oksana A. and Nefedova, Irina F. and Alekseev, Denis G. and Goncharenko, Sergei A.},
  title = {Physicochemical and biological profiles of a by-product of human donor plasma fractioning},
  journal = {Science and Innovations in Medicine},
  year = {2026},
  volume = {11},
  number = {4},
  pages = {261--268},
  doi = {10.35693/sim706425}
}
Start for free →